Columbia University, New York, New York (D.S.F., J.P.S., A.S., K.K.G., S.S.M.).
University of Florida, Gainesville, Florida (C.D.).
Ann Intern Med. 2018 Jun 5;168(11):783-790. doi: 10.7326/M17-3074. Epub 2018 May 8.
Prescription drug monitoring programs (PDMPs) are a key component of the president's Prescription Drug Abuse Prevention Plan to prevent opioid overdoses in the United States.
To examine whether PDMP implementation is associated with changes in nonfatal and fatal overdoses; identify features of programs differentially associated with those outcomes; and investigate any potential unintended consequences of the programs.
Eligible publications from MEDLINE, Current Contents Connect (Clarivate Analytics), Science Citation Index (Clarivate Analytics), Social Sciences Citation Index (Clarivate Analytics), and ProQuest Dissertations indexed through 27 December 2017 and additional studies from reference lists.
Observational studies (published in English) from U.S. states that examined an association between PDMP implementation and nonfatal or fatal overdoses.
2 investigators independently extracted data from and rated the risk of bias (ROB) of studies by using established criteria. Consensus determinations involving all investigators were used to grade strength of evidence for each intervention.
Of 2661 records, 17 articles met the inclusion criteria. These articles examined PDMP implementation only (n = 8), program features only (n = 2), PDMP implementation and program features (n = 5), PDMP implementation with mandated provider review combined with pain clinic laws (n = 1), and PDMP robustness (n = 1). Evidence from 3 studies was insufficient to draw conclusions regarding an association between PDMP implementation and nonfatal overdoses. Low-strength evidence from 10 studies suggested a reduction in fatal overdoses with PDMP implementation. Program features associated with a decrease in overdose deaths included mandatory provider review, provider authorization to access PDMP data, frequency of reports, and monitoring of nonscheduled drugs. Three of 6 studies found an increase in heroin overdoses after PDMP implementation.
Few studies, high ROB, and heterogeneous analytic methods and outcome measurement.
Evidence that PDMP implementation either increases or decreases nonfatal or fatal overdoses is largely insufficient, as is evidence regarding positive associations between specific administrative features and successful programs. Some evidence showed unintended consequences. Research is needed to identify a set of "best practices" and complementary initiatives to address these consequences.
National Institute on Drug Abuse and Bureau of Justice Assistance.
处方药物监测计划(PDMPs)是总统预防阿片类药物滥用计划的关键组成部分,旨在预防美国的阿片类药物过量。
研究 PDMP 的实施是否与非致命和致命药物过量有关;确定与这些结果相关的计划的不同特征;并调查该计划的任何潜在意外后果。
通过 MEDLINE、Current Contents Connect(Clarivate Analytics)、Science Citation Index(Clarivate Analytics)、Social Sciences Citation Index(Clarivate Analytics)和 ProQuest Dissertations 筛选出 2017 年 12 月 27 日之前发表的符合条件的出版物,以及从参考文献中筛选出的其他研究。
来自美国各州的观察性研究(以英文发表),研究了 PDMP 实施与非致命或致命药物过量之间的关联。
2 名调查员使用既定标准独立地从研究中提取数据并评估其偏倚风险(ROB)。涉及所有调查员的共识决定用于对每种干预措施的证据强度进行分级。
在 2661 条记录中,有 17 篇文章符合纳入标准。这些文章仅检查了 PDMP 的实施情况(n=8)、计划特征(n=2)、PDMP 的实施和计划特征(n=5)、PDMP 的实施与规定的提供者审查相结合与疼痛诊所法律(n=1)和 PDMP 稳健性(n=1)。有 3 项研究的证据不足以得出 PDMP 实施与非致命药物过量之间存在关联的结论。10 项研究提供了低强度证据,表明 PDMP 的实施减少了致命药物过量。与药物过量死亡相关的计划特征包括强制性提供者审查、提供者访问 PDMP 数据的授权、报告频率以及监测非处方药物。在 6 项研究中有 3 项发现 PDMP 实施后海洛因药物过量增加。
研究数量少、ROB 高、分析方法和结果测量方法多样。
PDMP 实施增加或减少非致命或致命药物过量的证据大多不足,而特定管理特征与成功计划之间存在积极关联的证据也是如此。一些证据表明存在意外后果。需要研究以确定一套“最佳实践”和补充措施来解决这些后果。
国家药物滥用研究所和司法援助局。